Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 0.74 |
| ▸ | CNR1 | P21554 | 6/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4385715 | 0.92 | CNR2 (0.70) | CNR2CNR1L3MBTL1MEN1KMT2A | |
| SCHEMBL3927424 | 0.90 | CNR2 (0.66) | CNR2CNR1L3MBTL1MEN1KMT2A | |
| SCHEMBL4382236 | 0.89 | CNR2 (0.65) | CNR2CNR1L3MBTL1MEN1KMT2A | |
| SCHEMBL4380764 | 0.89 | CNR2 (0.65) | CNR2CNR1L3MBTL1MEN1KMT2A | |
| SCHEMBL740116 | 0.86 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL4377147 | 0.86 | CNR2 (0.70) | CNR2CNR1 | |
| SCHEMBL3918717 | 0.86 | CNR2 (0.64) | CNR2CNR1 | |
| SCHEMBL738285 | 0.85 | CNR2 (1.00) | CNR2CNR1 | |
| SCHEMBL3927447 | 0.85 | CNR2 (0.69) | CNR2CNR1L3MBTL1MEN1KMT2A | |
| SCHEMBL3916550 | 0.84 | CNR2 (0.74) | CNR2CNR1MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | claimed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | PFIZER INC | 2009-12-03 | — | — | US | disclosed |
| EP-2114897-A2 | BENZIMIDAZOLONE DERIVATIVES | Pfizer Products Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008032164-A2 | BENZIMIDAZOLONE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298811-A1 | BENZIMIDAZOLONE DERIVATIVES | TRPV1, CNR1, CNR2 | CNR2 3/4885CNR1 2/4885L3MBTL1 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.